Led · Equity · Jan 2024

Kore offers a Product-Management-as-a-Service platform that provides end-to-end digital product management and embedded governance for financial services, creating full audit trails and digitising product processes. Its core tools support creation, management and monitoring of financial products from ideation to withdrawal with built-in controls for compliance and cross-department collaboration. The company has been revenue-generating since launch in 2019 and reports doubling revenues year-on-year with a recurring business model. Kore says its blue-chip customer base grew rapidly in 2023 (triple-digit customer growth reported) and two of the top four UK banks joined its roster. The business has expanded partnerships (including Capco and Protiviti), joined Barclays Rise accelerator, and recently appointed a new CFO to support growth. Recent investment is intended to accelerate market expansion into new geographies. Kore provides a SaaS platform for end-to-end product lifecycle management in financial services, creating a digital audit trail across products and functions in a single dashboard. Its solution offers regulatory oversight for senior managers, a cross-product management tool for specialists, and a product hub for frontline users. The company serves a blue-chip customer base, including major banking groups in Europe. Kore has been revenue-generating since its launch in 2019. The business intends to use the new funds to expand operations and broaden its market reach, with plans to enter new markets later this year. Sabrina Del Prete leads the company as CEO.

Led · Seed · Jul 2019

RevLifter is an AI-powered technology platform that enables brands to deliver real-time personalised offers and content across the eCommerce customer journey. Its platform is used by 100+ brands globally, including New Balance, Uniqlo, Staples, EE, Lowe’s, AO.com and Boohoo. The company processes more than 185 million online baskets every month and reported a 125% increase in revenues last year. RevLifter says it will relocate part of its business to the Catalyst in Newcastle and hire several new staff in the North East. The funding will also support the company’s push into the US market. RevLifter plans to launch a range of cutting-edge tools in 2022 to expand its product offering. RevLifter is a performance marketing technology company powered by AI that enables retailers and telecom providers to boost revenue through personalised incentives. Led by co-founders Simon Bird (CEO) and Ryan Kliszat (Chief Product Officer), the company provides a platform used by clients such as Harvey Nichols, Very, HP, Currys PC World, The Hut Group, AT&T, BT Broadband and EE. The company raised a £3.3m Series A to support its operations and growth. RevLifter says it will use the funds to continue rapid expansion into new markets. Its product focus is on delivering personalised, AI-driven incentives via its performance marketing platform. The company is based in London, UK. RevLifter personalises deals for retailers across any marketing channel. The platform uses AI to understand real-time signals from onsite user behaviour and deliver the right deal to the right customer at the right time to meet advertiser goals. Retailers use the service to drive outcomes such as new customer acquisition, higher average order value (AOV), and improved conversion rates. Customers include Carphone Warehouse (mobiles.co.uk), HP, Puma, EE, TM Lewin, Clarks, Verizon, AT&T, AO, and The Hut Group. Founded in 2017 by CEO Simon Bird and Chief Product & Strategy Officer Ryan Kliszat, the company is based in London, UK. Following a £2.3m seed funding round led by Coutts, RevLifter plans to use the proceeds to continue expanding operations and its business reach.

Led · Series A · Jan 2019

Fertility Focus develops OvuSense, an intravaginal monitor that measures core body temperature to detect minute temperature changes that mirror progesterone fluctuations and identify ovulation. The product helps women understand their cycles, diagnose cycle issues, and track the effects of medications. The company has also marketed the FertiloScope, a minimally invasive instrument for early diagnosis and immediate corrective surgery of physical causes of female infertility. Led by CEO Robert Milnes, Fertility Focus says it is continuously developing new technology to support women across stages of their fertility journeys. The company raised $2.7M in a Series A to accelerate commercialization and clinical work. It plans to use the funds to push further commercialization of OvuSense in North America and Europe and to conduct additional clinical trials. Fertility Focus is a Warwick, UK–based company led by CEO Robert Milnes that specializes in fertility diagnosis and treatment. Its core product, OvuSense, is a fertility monitor that identifies and predicts a woman’s fertile period and detects the absence of ovulation; OvuSense has already launched in Europe. The company also offers FertiloScope, a minimally invasive instrument for early diagnosis and immediate corrective surgery of physical causes of female infertility. Fertility Focus raised a seven-figure funding to support its growth. The capital will be used to expand the team and marketing and sales, obtain approval for OvuSense in the United States, and roll out products around the world. Founded in 2005 to license intellectual property from Bristol University, Fertility Focus develops minimally invasive products for diagnosis and treatment of female infertility. The company has developed two products: Fertiloscope, a minimally invasive instrument for early diagnosis and immediate corrective surgery of physical abnormalities (approved for sale in Europe and the USA), and the Advanced Fertility Monitor, which identifies and predicts periods of maximum fertility and can diagnose irregular ovulation. Led by CEO Robert Milnes, the company is establishing offices in the Warwick Technology Park and is based in Warwick, UK. Fertility Focus currently employs two staff and goes to market via a network of agents and distributors in Europe and worldwide. The company intends to use the new financing to complete regulatory approvals for the Advanced Fertility Monitor and to launch it into the European market.

Participated · Equity · Dec 2018

Lightpoint Medical develops intraoperative imaging products, notably a robotic laparoscopic probe designed to detect cancer in real time and the LightPath® Imaging System. The LightPath system has already achieved commercial sales throughout Europe. The laparoscopic probe is intended to bring real-time cancer detection to minimally invasive and robotic surgery to improve tissue-sparing and clinical outcomes. The company will use new funding to commercialise the laparoscopic probe and support commercial growth of the LightPath system. It has secured a £5 million financing and previously raised more than £3 million in grant funding from the Horizon 2020 SME Instrument and Innovate UK. Management says the funds will prepare the company for commercial scale-up and a commercial launch of the laparoscopic probe. Lightpoint Medical, based in Rickmansworth, United Kingdom and Cambridge, Massachusetts, develops the EnLight™ fiberscope system that uses molecular imaging to reveal microscopic cancer deposits. The technology is intended to enable surgeons to identify cancerous tissue during procedures. The company will use the awarded funds to support clinical trials of EnLight™ in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK). Lightpoint will collaborate on the research with MSK’s Drs. Jan Grimm and Nadeem Abu-Rustum. The company is led by Founder and CEO Dr. David Tuch and is backed by business angels and other private investors. Lightpoint Medical develops surgical imaging technologies, including its lead products LightPath™ and EnLight™, to help surgeons detect cancer in real time and reduce the need for repeat operations. The company has clinical trials underway in breast, prostate and stomach cancer. Led by CEO Dr David Tuch, Lightpoint is UK-based and completed a Series A raise of £2m ($3.1m). The company intends to use the funds to bring LightPath and EnLight to the US and European markets in 2015. Its technology is positioned for intraoperative cancer detection to improve surgical outcomes and reduce follow-up procedures. Lightpoint Medical is a Rickmansworth, UK–based developer of innovative imaging technologies for cancer surgery. Founded in 2012 by Dr David Tuch, the company is developing a novel molecular imaging technology based on Cerenkov luminescence imaging. The technology is intended to help surgeons detect cancer in real time during surgery, providing more accurate treatment while sparing healthy tissue. In June 2013 the company raised £175K (approximately $270K) in seed funding. The round involved a mix of institutional and angel investors led by Oxford Technology Management.